| scholarly article | Q13442814 |
| P50 | author | Everett E Vokes | Q73567428 |
| P2093 | author name string | Robert Kratzke | |
| Robert H Christenson | |||
| Xiaofei Wang | |||
| Martin J Edelman | |||
| Lydia Hodgson | |||
| Paula Y Rosenblatt | |||
| P2860 | cites work | Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. | Q35674750 |
| Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival | Q36608715 | ||
| Prognostic value of serum tumor markers in patients with lung cancer | Q43652784 | ||
| Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer | Q44569104 | ||
| Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments | Q44666296 | ||
| Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. | Q46748115 | ||
| Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer | Q47778363 | ||
| Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients | Q47981053 | ||
| Diagnostic Utility of Serum and Pleural Fluid Carcinoembryonic Antigen, Neuron-Specific Enolase, and Cytokeratin 19 Fragments in Patients With Effusions From Primary Lung Cancer | Q58198360 | ||
| Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC) | Q59274134 | ||
| Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response | Q73372503 | ||
| Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas | Q74294312 | ||
| Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients | Q78448054 | ||
| Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection | Q78681670 | ||
| Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC | Q79357646 | ||
| Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments | Q79362873 | ||
| Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer | Q80814833 | ||
| Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients | Q81262436 | ||
| Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer | Q83600544 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 649-654 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. | |
| P478 | volume | 7 |
| Q44710948 | A novel immunoassay for the quantization of CYFRA 21-1 in human serum. |
| Q86181816 | Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3 |
| Q37552206 | CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study |
| Q48506830 | Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging |
| Q36253580 | Chronic nasal exposure to nanoparticulate TiO2 causes pulmonary tumorigenesis in male mice |
| Q36889709 | Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer |
| Q41902053 | Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer |
| Q36912416 | Direct detection of cancer biomarkers in blood using a "place n play" modular polydimethylsiloxane pump |
| Q30316699 | Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. |
| Q37689082 | Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. |
| Q38947077 | History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer |
| Q50107843 | Measurement of Lung Cancer Tumor Markers in a Glass Wool Company Workers Exposed to Respirable Synthetic Vitreous Fiber and Dust. |
| Q92657202 | New Immunosensing-Fluorescence Detection of Tumor Marker Cytokeratin-19 Fragment (CYFRA 21-1) Via Carbon Quantum Dots/Zinc Oxide Nanocomposite |
| Q34860000 | Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study |
| Q37744346 | Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer |
| Q88795025 | Pulmonary adenocarcinoma associated with Guillain-Barré syndrome: A case report |
| Q33829604 | Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer |
| Q88691095 | Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer |
| Q47447106 | Serum cytokeratin 19 fragment 21-1 is a useful tumor marker for the assessment of extramammary Paget's disease. |
| Q47151967 | Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. |
| Q28066963 | Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis |
| Q36268128 | The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients |
| Q96816703 | The interaction between ferroptosis and lipid metabolism in cancer |
| Q36336377 | Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer |
Search more.